HighTower Advisors’s AIM ImmunoTech AIM Stock Holding History

HighTower Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-241	Closed	-$22K	–	3805
2021 Q4	$22K	Sell	241 -170	-41%	-$26.3K	﹤0.01%	3102
2021 Q3	$82K	Sell	411 -261	-39%	-$52.7K	﹤0.01%	2871
2021 Q2	$144K	Buy	672 +40	+6%	+$8.57K	﹤0.01%	2733
2021 Q1	$143K	Buy	+632	New	+$143K	﹤0.01%	2688
2020 Q4	–	Sell	-701	Closed	-$151K	–	3073
2020 Q3	$151K	Buy	701 +401	+134%	+$100K	﹤0.01%	2161
2020 Q2	$75K	Buy	+300	New	+$72.8K	﹤0.01%	2163

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors's AIM Position: Q1 2022 in Review

HighTower Advisors sold out of AIM ImmunoTech (AIM) in Q1 2022, closing a stake of 241 shares — an estimated $22K sold.

HighTower Advisors first reported a position in AIM in Q2 2020 and held it in 6 quarters. The position peaked at $151K in Q3 2020. 35 funds tracked by Wall St. Rank hold AIM as of Q1 2022.

HighTower Advisors reported no remaining AIM ImmunoTech position as of Q1 2022 after selling out during the quarter.
HighTower Advisors sold 241 AIM ImmunoTech shares in Q1 2022, an estimated $22K.
HighTower Advisors first reported a position in AIM ImmunoTech in Q2 2020 and held it in 6 quarters.
HighTower Advisors's AIM ImmunoTech position peaked at $151K in Q3 2020.
35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.